Skip to content

Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer

Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03017560
Enrollment
45
Registered
2017-01-11
Start date
2015-12-31
Completion date
2017-05-31
Last updated
2023-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Treatment, Cognitive Deficits

Keywords

Breast Cancer, Chemotherapy, Verbal Memory, Processing Speed

Brief summary

The primary purpose of this study is to test the effects of a targeted, computerized cognitive training program on verbal memory in older women who have undergone chemotherapy treatment for early-stage breast cancer. As measured by neuropsychological assessment, this treatment will result in improved verbal memory. Secondarily, processing speed and naming abilities are expected to improve. Enhanced self-perception of cognitive ability is also expected.

Interventions

Participants will engage in auditory and verbal memory exercises intended to improve verbal memory functioning. The exercises are: Elephant Memory, Words where are you?, Split words, Bird Songs, Sound check, and You've got voicemail. Participants will complete the exercises 1 hour per day, 6 days per week, for 6 weeks. The program automatically adjusts difficulty level according to individual performance. The program captures and reports all relevant data to the primary investigator, including accuracy and reaction time (speed), which will be used to measure progress.

Sponsors

Shirley Ryan AbilityLab
CollaboratorOTHER
Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
65 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Women ages 65-90 * Chemotherapy treatment for early-stage (I, IIa, IIb, IIIa) breast cancer * Post-menopausal * High school education or greater * Geographically available for followup assessment * Native English speaker * Normal or corrected to near-normal hearing and vision

Exclusion criteria

* Psychiatric history including past or current psychotic spectrum disorders (schizophrenia, bipolar disorder, major depressive disorder, dementia, schizoaffective disorder) * Brain injury (e.g., stroke, heart attack, aneurysm, tumor, concussion, head trauma) * Brain disease * History of brain irradiation or surgery * Current or past disease/disorder of the central nervous system or medical condition affecting cognitive functioning (e.g., chronic migraine, epilepsy or history of seizures, encephalitis, meningitis, multiple sclerosis, thyroid condition, Parkinson's, Alzheimer's, Huntington's disease) * Active diagnosis of autoimmune or inflammatory disorder (e.g., systemic lupus erythematosus, rheumatoid arthritis, vasculitis, insulin-dependent diabetes, Crohn's disease, uncontrolled allergic reaction or asthma) * History of other cancer, except for basal cell carcinoma * Development of a second primary malignancy during the study * Drug or alcohol abuse (i.e., more than 7 drinks per week) * Chronic use of oral steroid medication * Former (prior to early-stage breast cancer) intrathecal therapy, radiation therapy, chemotherapy, or any neoadjuvant chemotherapy * Acquired or developmental speech, language, or learning disorders (e.g., aphasia, dyslexia, dysgraphia, auditory processing disorder, autism, developmental delay) * Hormone replacement therapy, excluding vaginal estrogen

Design outcomes

Primary

MeasureTime frameDescription
Verbal MemoryChange in Verbal Memory scores from Pretreatment/Baseline to Posttreatment/6 weeks, from Posttreatment/6 weeks to 1 month followup/10 weeks, and from Pretreatment/Baseline to 1 month followup/10 weeks.Immediate and delayed verbal memory

Secondary

MeasureTime frameDescription
Processing Speed measured via Lexical Decision TaskChange in Processing Speed scores from Pretreatment/Baseline to Posttreatment/6 weeks, from Posttreatment/6 weeks to 1 month followup/10 weeks, and from Pretreatment/Baseline to 1 month followup/10 weeksThe Lexical Decision Task is a computerized task that measures processing speed by calculating reaction times to verb and non-verb stimuli. Outcome is measured by reaction time in milliseconds.
Processing Speed measured via Stroop Color-Word TestChange in Processing Speed scores from Pretreatment/Baseline to Posttreatment/6 weeks, from Posttreatment/6 weeks to 1 month followup/10 weeks, and from Pretreatment/Baseline to 1 month followup/10 weeksThe Stroop Color-Word task is a paper and pencil task that measures processing speed by assessing correct number of words read, correct number of color names read, and correct number of color-word interference pairs (i.e., names of colors printed in non-matching ink colors) read in 45 seconds. Outcomes are measured in raw scores and associated T-scores referenced against sex+age normative groups. The Stroop Color-Word Test scores will not be aggregated with the Lexical Decision Task scores.

Other

MeasureTime frameDescription
The Functional Assessment of Cancer Therapy-CognitionPre-treatment/Baseline, Post-treatment/6 weeks, 1 month followup/10 weeksSelf-perception of cognitive ability
Treatment satisfaction surveyPre-treatment/Baseline, Post-treatment/6 weeks, 1 month followup/10 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026